Immunochina Pharmaceuticals Raises Funds for Gene Therapy Development
Beijing-based gene therapy specialist Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in...
Cell-therapy
Allogene Overland Biopharm Completes State-of-the-Art AlloCAR T Facility in Shanghai
Allogene Overland Biopharm, a joint venture between Overland Pharmaceuticals and Allogene Therapeutics, Inc. (NASDAQ: ALLO),...
JW Therapeutics Partners with 2seventy bio to Develop Cell Therapy Platform
China-based JW Therapeutics (HKG: 2126) has entered into a partnership with US firm 2seventy bio...
OriginCell’s CAR-T Therapy Receives FDA Orphan Drug Designation for Multiple Myeloma
Shanghai-based tumor immunotherapy specialist OriginCell Therapeutics has announced that its investigational autologous chimeric antigen receptor...
Celgenyx Completes RMB 100M Series A Financing for Next-Gen Cell Therapy Development
China-based Hangzhou Celgenyx Gene Technology Co., Ltd has announced the completion of a Series A...
Kactus Biosystems Raises RMB 200M in Series B Financing for Protein and Enzyme Development
Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has raised RMB...
GenScript’s Legend Biotech Reports USD 55M in Carvykti Sales
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that sales of...
Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion
Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial...
Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients
China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion...
Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...
CARsgen’s BCMA-Targeted CAR-T Therapy CT053 Gains Priority Review in China
The Center for Drug Evaluation (CDE) website indicates that China-based chimeric antigen receptor (CAR)-T cell...
IASO Biotherapeutics Licenses CD19 Binder to Cabaletta Bio for Autoimmune Diseases
China-based IASO Biotherapeutics has announced a licensing agreement with US firm Cabaletta Bio Inc. (NASDAQ:...
NMPA Approves JW Therapeutics’ Carteyva for Recurrent Follicular Lymphoma
The National Medical Products Administration (NMPA) has granted another indication approval to China-based JW Therapeutics’...
Biosyngen’s First-in-Class Drug Candidate BRG01 Accepted for IND Review
Biosyngen has announced that its investigational new drug (IND) filing for the first-in-class (FIC) drug...
Biosyngen to Establish Cell Therapy GMP Facility in Singapore
Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...
Legend Biotech’s Carvykti Approved in Japan for Relapsed Multiple Myeloma
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that Japan’s Ministry of Health, Labour and...
Eureka Biotech Partners with Ucello for Universal CAR-T Cell Therapy Development
Shenzhen Eureka Biotechnology Co., Limited, a China-based biotech firm, has entered into a partnership with...
Global Cord Blood Corporation Appoints Liquidators Amid Shareholder Dispute
Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman...
Ubrigene Raises Hundreds of Millions in Series C Financing Round
Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy...
CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit
China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...